top of page



Klara Czobor

Klara Czobor

Ms. Czobor excels in conducting due diligence, market research, and competitive intelligence (CI) projects. Ms. Czobor’s expert, in-depth interviewing skills allow her to uncover valuable information, which enables clients to address their business challenges head-on. She also excels at recruiting definitive target audiences for any live or online activity.


Ms. Czobor has over 15 years of medical research experience, encompassing a wide variety of therapeutic areas. As a senior Pharmaceutical Analyst/Reporter at the Financial Times Group, she was responsible for providing real-time, comprehensive information/CI to the pharmaceutical and investment community on therapies for the treatment of malignancies such as prostate, colon, and breast cancer, and respiratory conditions such as pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). Ms. Czobor provided eye-catching coverage of the pivotal C-08 trial of Avastin in colon cancer. She uncovered, well ahead of competing publications, that the C-08 study would not meet its primary endpoint.

Medical Affairs Consultant

Dr. Lucia Mokres

Dr. Lucia Mokres is a Life Science Entrepreneurial Consultant based in the San Francisco Bay Area. She specializes in coaching early stage companies through stakeholder and ecosystem discovery, allowing them to gain traction and develop an investable technology and business model.  She helps companies at all stages work through medical, scientific, regulatory, and clinical challenges.


Previously, Dr. Mokres was the Chief Medical Officer of EpiBiome, Inc. In this role, she leveraged her clinical, research, and industry background to provide medical oversight and strategic direction for all clinical development activities, defined regulatory strategy, supported marketing and business development activities, and served as the medical point of contact for external stakeholders. She was a key contributor for investor pitches and was an invited speaker nationally and internationally on the challenges faced by early stage companies seeking product approval or clearance. She led EpiBiome through the NSF Innovation Corps and several other incubators and accelerators.


Prior to joining EpiBiome, Dr. Mokres served as a medical advisor and program manager in the medical device industry.  She completed her post doctorate at Stanford University School of Medicine.

Stephen Strudwick
Dr. Lucia Mokres


Stephen Strudwick, PhD

Dr. Strudwick translates preclinical and clinical information and generates messaging for key healthcare stakeholders. Dr. Strudwick provides clients with strategic medical and marketing guidance on due diligence, market research, competitive intelligence, and medical education initiatives. He excels at identifying and addressing medical/marketing opportunities and challenges for established and emerging therapies and medical devices.


Dr. Strudwick has over 18 years of medical research experience, encompassing a wide variety of therapeutic areas. Throughout his career in medical communications, he was responsible for maintaining the medical integrity and relevance of key health care product accounts and providing strategic medical and marketing guidance to clients. He has a comprehensive knowledge of the clinical profiles and marketing strategies that support products with diverse indications such as metastatic cancer, psychiatric and neurologic disorders, and rare/orphan diseases.


Dr.  Weiqing Wang

Dr. Wang has over 20 years of scientific research experience in biochemistry. Dr. Wang received her PhD in biochemistry from the Chinese Academy of Sciences and then received her postdoctoral training in biochemistry at the Albert Einstein College of Medicine.


Subsequently, Dr. Wang worked as a Scientist at the Memorial Sloan-Kettering Cancer Center for 10 years. Dr. Wang’s research interests include the molecular biology of tumors, genomics, proteomics and bioinformatics. She has published basic research papers on cancer biology in top-tier journals such as Nature and in the Proceedings of the National Academy of Sciences.

Dr. Weiqing Wang
bottom of page